Marburg Hemorrhagic Fever - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Marburg Hemorrhagic Fever - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Marburg Hemorrhagic Fever - Pipeline Review, H1 2015', provides an overview of the Marburg Hemorrhagic Fever's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Marburg Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Marburg Hemorrhagic Fever and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Marburg Hemorrhagic Fever and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Marburg Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Marburg Hemorrhagic Fever pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Marburg Hemorrhagic Fever Overview 6
Therapeutics Development 7
Pipeline Products for Marburg Hemorrhagic Fever - Overview 7
Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis 8
Marburg Hemorrhagic Fever - Therapeutics under Development by Companies 9
Marburg Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes 10
Marburg Hemorrhagic Fever - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Marburg Hemorrhagic Fever - Products under Development by Companies 13
Marburg Hemorrhagic Fever - Products under Investigation by Universities/Institutes 14
Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development 15
GlaxoSmithKline plc 15
Immunovaccine, Inc. 16
Integrated BioTherapeutics, Inc. 17
Sarepta Therapeutics, Inc. 18
Tekmira Pharmaceuticals Corp. 19
Vaxart, Inc. 20
Marburg Hemorrhagic Fever - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AVI-7288 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ebola + marburg vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
marburg vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
marburg vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
marburg virus vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody for Marburg Virus - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
panfilovirus (multivalent) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TKM-Marburg - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Marburg Hemorrhagic Fever - Recent Pipeline Updates 39
Marburg Hemorrhagic Fever - Dormant Projects 41
Marburg Hemorrhagic Fever - Product Development Milestones 42
Featured News & Press Releases 42
Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate 42
Nov 12, 2013: Tekmira Announces New Preclinical Data On TKM-Marburg 42
Oct 08, 2013: Tekmira Provides Corporate Update On RNAi Therapeutics Product TKM-Marburg 43
Sep 25, 2013: Tekmira Presents New Anti-Viral Efficacy Data Against the Marburg Hemorrhagic Fever Virus 44
May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus 45
Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for Marburg Hemorrhagic Fever, H1 2015 7
Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Marburg Hemorrhagic Fever - Pipeline by GlaxoSmithKline plc, H1 2015 15
Marburg Hemorrhagic Fever - Pipeline by Immunovaccine, Inc., H1 2015 16
Marburg Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H1 2015 17
Marburg Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H1 2015 18
Marburg Hemorrhagic Fever - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 19
Marburg Hemorrhagic Fever - Pipeline by Vaxart, Inc., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Assessment by Combination Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Marburg Hemorrhagic Fever Therapeutics - Recent Pipeline Updates, H1 2015 39
Marburg Hemorrhagic Fever - Dormant Projects, H1 2015 41